Hao Dai; Yongqiu Li; Yao An Lee; et al. JAMA Oncol. Published online August 21, 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for glycemic control in type 2 diabetes and have recently gained popularity for weight management. We compared the incidence of 14 cancers among adults with obesity prescribed GLP-1RAs vs nonusers. A total of 86 632 matched adults were included, comprising 43 317 GLP-1RA users and 43 315 taking GLP-1RAs may be associated with an increased risk of kidney cancer, highlighting the need for longer-term follow-up to clarify the underlying mechanisms and clinical implications of these findings.ovarian, and meningioma cancers, among patients with obesity or overweight. However,otherwise eligible nonusers. The incidence rates of the 14 cancers were 13.6 vs 16.4 per 1000 person-years, respectively, indicating a significantly lower overall cancer risk among individuals taking GLP-1RAs (hazard ratio 0.83; P = .002) compared with nonusers. In particular, taking GLP-1RAs was associated with a reduced risk of endometrial cancer, ovarian cancer, and meningioma. This retrospective cohort study found that taking GLP-1Ras was associated with a reduced overall risk of cancer, including lower risks of endometrial,
24 Mar, 2026